{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:56:21Z","timestamp":1791060981715,"version":"4.1.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Non-tuberculous mycobacteria (NTM) can present a serious clinical threat due to their resistance to conventional antibiotics and their ability to cause persistent infections. As antimicrobial resistance (AMR) represents one of the most significant global health threats, mycobacteriophages (MPs)\u2014viruses that specifically target mycobacterial species\u2014are emerging as a promising therapeutic addition or alternative. This review explores the biological characteristics, therapeutic mechanisms, and clinical potential of MPs, with a primary focus on their use against NTM infections. Based on data from\n                    <jats:italic>in vitro<\/jats:italic>\n                    \u00a0studies, animal models, and human compassionate-use cases, we highlight the mycobactericidal efficacy of MPs as well as their potential to complement antibiotic treatment regimens. However, there are key challenges that need to be addressed to implement MPs as therapeutics\u2014such as limited host range, immune response interference, MP resistance, and intracellular delivery barriers. The implementation of MP banks, standardized regulatory protocols, and approved clinical trials is highly essential for MP therapy to transition smoothly into the healthcare sectors. By carrying out coordinated scientific, regulatory, and clinical efforts, MP-based therapy holds a promising potential in combating antibiotic-resistant NTM infections.\n                  <\/jats:p>","DOI":"10.1007\/s15010-026-02818-7","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:00:38Z","timestamp":1780300838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the next \u201cphage\u201d of treating non-tuberculous mycobacterial infections"],"prefix":"10.1007","author":[{"given":"Max","family":"Kevane-Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Idris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"W\u00fcrstle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Lieberknecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J. G. T.","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Wichelhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Wetzstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"2818_CR1","unstructured":"Genus, Mycobacterium. Apr. https:\/\/lpsn.dsmz.de\/genus\/mycobacterium. Accessed 9 2025."},{"key":"2818_CR2","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1128\/JCM.01287-16","volume":"55","author":"BA Forbes","year":"2017","unstructured":"Forbes BA. Mycobacterial taxonomy. J Clin Microbiol. 2017;55:380\u20133. https:\/\/doi.org\/10.1128\/JCM.01287-16.","journal-title":"J Clin Microbiol"},{"key":"2818_CR3","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1128\/jb.00485-12","volume":"194","author":"AM Abdallah","year":"2012","unstructured":"Abdallah AM, Rashid M, Adroub SA, Arnoux M, Ali S, van Soolingen D, et al. Complete genome sequence of Mycobacterium phlei type strain RIVM601174. J Bacteriol. 2012;194:3284\u20135. https:\/\/doi.org\/10.1128\/jb.00485-12.","journal-title":"J Bacteriol"},{"key":"2818_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3389\/fcimb.2018.00158","volume":"8","author":"Q Chai","year":"2018","unstructured":"Chai Q, Zhang Y, Liu CH. Mycobacterium tuberculosis: an adaptable pathogen associated with multiple human diseases. Front Cell Infect Microbiol. 2018;8:158. https:\/\/doi.org\/10.3389\/fcimb.2018.00158.","journal-title":"Front Cell Infect Microbiol"},{"key":"2818_CR5","doi-asserted-by":"publisher","unstructured":"Percival SL, Williams DW. Chapter Nine - Mycobacterium. In: Percival SL, Yates MV, Williams DW, Chalmers RM, Gray NF, editors. Microbiology of Waterborne Diseases (Second Edition). London: Academic Press; 2014. pp. 177\u2013207. https:\/\/doi.org\/10.1016\/B978-0-12-415846-7.00009-3","DOI":"10.1016\/B978-0-12-415846-7.00009-3"},{"key":"2818_CR6","doi-asserted-by":"publisher","unstructured":"Alonso-Hearn M, Abenda\u00f1o N, Ruvira MA, Aznar R, Landin M, Juste RA. Mycobacterium avium subsp. paratuberculosis (Map) Fatty Acids Profile Is Strain-Dependent and Changes Upon Host Macrophages Infection. Front Cell Infect Microbiol. 2017;7. https:\/\/doi.org\/10.3389\/fcimb.2017.00089.","DOI":"10.3389\/fcimb.2017.00089"},{"key":"2818_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/s0065-2911(08)60016-8","volume":"39","author":"M Daff\u00e9","year":"1998","unstructured":"Daff\u00e9 M, Draper P. The envelope layers of mycobacteria with reference to their pathogenicity. Adv Microb Physiol. 1998;39:131\u2013203. https:\/\/doi.org\/10.1016\/s0065-2911(08)60016-8.","journal-title":"Adv Microb Physiol"},{"key":"2818_CR8","doi-asserted-by":"publisher","unstructured":"Brennan PJ. Structure of mycobacteria: recent developments in defining cell wall carbohydrates and proteins. Rev Infect Dis. 1989;11. https:\/\/doi.org\/10.1093\/clinids\/11.supplement_2.s420. :S420-430.","DOI":"10.1093\/clinids\/11.supplement_2.s420"},{"key":"2818_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1574-6968.1994.tb07194.x","volume":"123","author":"V Jarlier","year":"1994","unstructured":"Jarlier V, Nikaido H. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol Lett. 1994;123:11\u20138. https:\/\/doi.org\/10.1111\/j.1574-6968.1994.tb07194.x.","journal-title":"FEMS Microbiol Lett"},{"key":"2818_CR10","doi-asserted-by":"publisher","unstructured":"Jacobo-Delgado YM, Rodr\u00edguez-Carlos A, Serrano CJ, Rivas-Santiago B. Mycobacterium tuberculosis cell-wall and antimicrobial peptides: a mission impossible? Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1194923.","DOI":"10.3389\/fimmu.2023.1194923"},{"key":"2818_CR11","doi-asserted-by":"publisher","first-page":"6428","DOI":"10.1021\/acs.orglett.2c02518","volume":"24","author":"K Shen","year":"2022","unstructured":"Shen K, Lowary TL. Synthesis of the Mycobacterium tuberculosis Canetti Lipooligosaccharide II Nonasaccharide. Org Lett. 2022;24:6428\u201332. https:\/\/doi.org\/10.1021\/acs.orglett.2c02518.","journal-title":"Org Lett"},{"key":"2818_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1017\/S0031182016002377","volume":"145","author":"KA Abrahams","year":"2018","unstructured":"Abrahams KA, Besra GS. Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target. Parasitology. 2018;145:116\u201333. https:\/\/doi.org\/10.1017\/S0031182016002377.","journal-title":"Parasitology"},{"key":"2818_CR13","doi-asserted-by":"publisher","first-page":"809014","DOI":"10.1155\/2015\/809014","volume":"2015","author":"S Faria","year":"2015","unstructured":"Faria S, Joao I, Jordao L. General overview on nontuberculous mycobacteria, biofilms, and human infection. J Pathog. 2015;2015:809014. https:\/\/doi.org\/10.1155\/2015\/809014.","journal-title":"J Pathog"},{"key":"2818_CR14","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.3390\/jcm9082541","volume":"9","author":"K To","year":"2020","unstructured":"To K, Cao R, Yegiazaryan A, Owens J, Venketaraman V. General overview of nontuberculous mycobacteria opportunistic pathogens: mycobacterium avium and Mycobacterium abscessus. J Clin Med. 2020;9:2541. https:\/\/doi.org\/10.3390\/jcm9082541.","journal-title":"J Clin Med"},{"key":"2818_CR15","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1183\/09031936.00149212","volume":"42","author":"W Hoefsloot","year":"2013","unstructured":"Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42:1604\u201313. https:\/\/doi.org\/10.1183\/09031936.00149212.","journal-title":"Eur Respir J"},{"key":"2818_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ccm.2023.08.012","volume":"44","author":"DR Prevots","year":"2023","unstructured":"Prevots DR, Marshall JE, Wagner D, Morimoto K. Global epidemiology of nontuberculous mycobacterial pulmonary disease: a review. Clin Chest Med. 2023;44:675\u2013721. https:\/\/doi.org\/10.1016\/j.ccm.2023.08.012.","journal-title":"Clin Chest Med"},{"key":"2818_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13073-024-01359-8","volume":"16","author":"N Wetzstein","year":"2024","unstructured":"Wetzstein N, Diricks M, Anton TB, Andres S, Kuhns M, Kohl TA, et al. Clinical and genomic features of Mycobacterium avium complex: a multi-national European study. Genome Med. 2024;16:86. https:\/\/doi.org\/10.1186\/s13073-024-01359-8.","journal-title":"Genome Med"},{"key":"2818_CR18","doi-asserted-by":"publisher","first-page":"e0007083","DOI":"10.1371\/journal.pntd.0007083","volume":"13","author":"SL Baldwin","year":"2019","unstructured":"Baldwin SL, Larsen SE, Ordway D, Cassell G, Coler RN. The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases. PLoS Negl Trop Dis. 2019;13:e0007083. https:\/\/doi.org\/10.1371\/journal.pntd.0007083.","journal-title":"PLoS Negl Trop Dis"},{"key":"2818_CR19","doi-asserted-by":"publisher","first-page":"100244","DOI":"10.1016\/j.jctube.2021.100244","volume":"24","author":"KM Pennington","year":"2021","unstructured":"Pennington KM, Vu A, Challener D, Rivera CG, Shweta FNU, Zeuli JD, et al. Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease. J Clin Tuberc Mycobact Dis. 2021;24:100244. https:\/\/doi.org\/10.1016\/j.jctube.2021.100244.","journal-title":"J Clin Tuberc Mycobact Dis"},{"key":"2818_CR20","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jfma.2020.05.028","volume":"119","author":"Y-W Weng","year":"2020","unstructured":"Weng Y-W, Huang C-K, Sy C-L, Wu K-S, Tsai H-C, Lee SS-J. Treatment for Mycobacterium abscessus complex\u2013lung disease. J Formos Med Assoc. 2020;119:S58\u201366. https:\/\/doi.org\/10.1016\/j.jfma.2020.05.028.","journal-title":"J Formos Med Assoc"},{"key":"2818_CR21","doi-asserted-by":"publisher","first-page":"1394220","DOI":"10.3389\/fmicb.2024.1394220","volume":"15","author":"LE Conyers","year":"2024","unstructured":"Conyers LE, Saunders BM. Treatment for non-tuberculous mycobacteria: challenges and prospects. Front Microbiol. 2024;15:1394220. https:\/\/doi.org\/10.3389\/fmicb.2024.1394220.","journal-title":"Front Microbiol"},{"key":"2818_CR22","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1128\/AAC.04577-14","volume":"59","author":"BY Lee","year":"2015","unstructured":"Lee BY, Kim S, Hong Y, Lee S-D, Kim WS, Kim DS, et al. Risk factors for recurrence after successful treatment of mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2015;59:2972\u20137. https:\/\/doi.org\/10.1128\/AAC.04577-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"2818_CR23","doi-asserted-by":"publisher","first-page":"1801038","DOI":"10.1183\/13993003.01038-2018","volume":"53","author":"BS Kwon","year":"2019","unstructured":"Kwon BS, Shim TS, Jo K-W. The second recurrence of Mycobacterium avium complex lung disease after successful treatment for first recurrence. Eur Respir J. 2019;53:1801038. https:\/\/doi.org\/10.1183\/13993003.01038-2018.","journal-title":"Eur Respir J"},{"key":"2818_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1183\/09031936.00024008","volume":"33","author":"M Santin","year":"2009","unstructured":"Santin M, Dorca J, Alcaide F, Gonzalez L, Casas S, Lopez M, et al. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease. Eur Respir J. 2009;33:148\u201352. https:\/\/doi.org\/10.1183\/09031936.00024008.","journal-title":"Eur Respir J"},{"key":"2818_CR25","doi-asserted-by":"publisher","first-page":"9040","DOI":"10.1038\/s41598-021-88291-8","volume":"11","author":"SE Larsen","year":"2021","unstructured":"Larsen SE, Reese VA, Pecor T, Berube BJ, Cooper SK, Brewer G, et al. Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models. Sci Rep. 2021;11:9040. https:\/\/doi.org\/10.1038\/s41598-021-88291-8.","journal-title":"Sci Rep"},{"key":"2818_CR26","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.vaccine.2020.11.045","volume":"39","author":"LF Pittet","year":"2021","unstructured":"Pittet LF, Tebruegge M, Dutta B, Donath S, Messina N, Casalaz D, et al. Mycobacterium ulcerans-specific immune response after immunisation with bacillus Calmette-Gu\u00e9rin (BCG) vaccine. Vaccine. 2021;39:652\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.045.","journal-title":"Vaccine"},{"key":"2818_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12929-024-01007-8","volume":"31","author":"M Casanova","year":"2024","unstructured":"Casanova M, Maresca M, Poncin I, Point V, Olleik H, Boidin-Wichlacz C, et al. Promising antibacterial efficacy of arenicin peptides against the emerging opportunistic pathogen Mycobacterium abscessus. J Biomed Sci. 2024;31:18. https:\/\/doi.org\/10.1186\/s12929-024-01007-8.","journal-title":"J Biomed Sci"},{"key":"2818_CR28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1099\/jmm.0.000912","volume":"68","author":"E Portell-Buj","year":"2019","unstructured":"Portell-Buj E, Vergara A, Alejo I, L\u00f3pez-Gav\u00edn A, Mont\u00e9 MR, San Nicol\u00e1s L, et al. In vitro activity of 12 antimicrobial peptides against Mycobacterium tuberculosis and Mycobacterium avium clinical isolates. J Med Microbiol. 2019;68:211\u20135. https:\/\/doi.org\/10.1099\/jmm.0.000912.","journal-title":"J Med Microbiol"},{"key":"2818_CR29","doi-asserted-by":"publisher","first-page":"e02924","DOI":"10.1128\/mbio.02924-23","volume":"15","author":"AA Schmalstig","year":"2023","unstructured":"Schmalstig AA, Wiggins A, Badillo D, Wetzel KS, Hatfull GF, Braunstein M. Bacteriophage infection and killing of intracellular Mycobacterium abscessus. mBio. 2023;15:e02924\u201323. https:\/\/doi.org\/10.1128\/mbio.02924-23.","journal-title":"mBio"},{"key":"2818_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s41030-022-00210-y","volume":"9","author":"GF Hatfull","year":"2023","unstructured":"Hatfull GF. Phage therapy for nontuberculous mycobacteria: challenges and opportunities. Pulm Ther. 2023;9:91\u2013107. https:\/\/doi.org\/10.1007\/s41030-022-00210-y.","journal-title":"Pulm Ther"},{"key":"2818_CR31","doi-asserted-by":"publisher","first-page":"e28365","DOI":"10.4161\/bact.28365","volume":"4","author":"EC Keen","year":"2014","unstructured":"Keen EC. Tradeoffs in bacteriophage life histories. Bacteriophage. 2014;4:e28365. https:\/\/doi.org\/10.4161\/bact.28365.","journal-title":"Bacteriophage"},{"key":"2818_CR32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.resmic.2008.05.001","volume":"159","author":"AM Comeau","year":"2008","unstructured":"Comeau AM, Hatfull GF, Krisch HM, Lindell D, Mann NH, Prangishvili D. Exploring the prokaryotic virosphere. Res Microbiol. 2008;159:306\u201313. https:\/\/doi.org\/10.1016\/j.resmic.2008.05.001.","journal-title":"Res Microbiol"},{"key":"2818_CR33","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1073\/pnas.96.5.2192","volume":"96","author":"RW Hendrix","year":"1999","unstructured":"Hendrix RW, Smith MCM, Burns RN, Ford ME, Hatfull GF. Evolutionary relationships among diverse bacteriophages and prophages: all the world\u2019s a phage. Proc Natl Acad Sci U S A. 1999;96:2192\u20137. https:\/\/doi.org\/10.1073\/pnas.96.5.2192.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2818_CR34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1128\/AAC.45.3.649-659.2001","volume":"45","author":"A Sulakvelidze","year":"2001","unstructured":"Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45:649\u201359. https:\/\/doi.org\/10.1128\/AAC.45.3.649-659.2001.","journal-title":"Antimicrob Agents Chemother"},{"key":"2818_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4161\/bact.1.1.14942","volume":"1","author":"MR Clokie","year":"2011","unstructured":"Clokie MR, Millard AD, Letarov AV, Heaphy S. Phages in nature. Bacteriophage. 2011;1:31\u201345. https:\/\/doi.org\/10.4161\/bact.1.1.14942.","journal-title":"Bacteriophage"},{"key":"2818_CR36","doi-asserted-by":"publisher","unstructured":"Chanishvili N. Chapter 1 - Phage Therapy\u2014History from Twort and d\u2019Herelle Through Soviet Experience to Current Approaches. In: \u0141obocka M, Szybalski W, editors. Advances in Virus Research. Academic; 2012. pp. 3\u201340. https:\/\/doi.org\/10.1016\/B978-0-12-394438-2.00001-3.","DOI":"10.1016\/B978-0-12-394438-2.00001-3"},{"issue":"Suppl 13","key":"2818_CR37","doi-asserted-by":"publisher","first-page":"e2020024","DOI":"10.23750\/abm.v91i13-S.10819","volume":"91","author":"Z Naureen","year":"2020","unstructured":"Naureen Z, Dautaj A, Anpilogov K, Camilleri G, Dhuli K, Tanzi B, et al. Bacteriophages presence in nature and their role in the natural selection of bacterial populations. Acta Bio Med Atenei Parm. 2020;91(Suppl 13):e2020024. https:\/\/doi.org\/10.23750\/abm.v91i13-S.10819.","journal-title":"Acta Bio Med Atenei Parm"},{"key":"2818_CR38","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1126\/science.1174173","volume":"325","author":"M Vos","year":"2009","unstructured":"Vos M, Birkett PJ, Birch E, Griffiths RI, Buckling A. Local adaptation of bacteriophages to their bacterial hosts in soil. Science. 2009;325:833\u2013833. https:\/\/doi.org\/10.1126\/science.1174173.","journal-title":"Science"},{"key":"2818_CR39","unstructured":"Steward K. Lytic vs Lysogenic \u2013 understanding bacteriophage life cycles. Immunology & Microbiology from Technology Networks. 2018."},{"key":"2818_CR40","unstructured":"White HE, Orlova EV, Bacteriophages. Their Structural Organisation and Function | IntechOpen. IntechOpen; 2020."},{"key":"2818_CR41","unstructured":"Mansour NM. Bacteriophages are natural gift, could we pay further attention! J Food Microbiol. 2018;0."},{"key":"2818_CR42","doi-asserted-by":"publisher","unstructured":"Zhang Y, Guo Y, Qiu T, Gao M, Wang X, Bacteriophages. Underestimated vehicles of antibiotic resistance genes in the soil. Front Microbiol. 2022;13. https:\/\/doi.org\/10.3389\/fmicb.2022.936267.","DOI":"10.3389\/fmicb.2022.936267"},{"key":"2818_CR43","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.3390\/v14091904","volume":"14","author":"M Zhang","year":"2022","unstructured":"Zhang M, Zhang T, Yu M, Chen Y-L, Jin M. The life cycle transitions of temperate phages: regulating factors and potential ecological implications. Viruses. 2022;14:1904. https:\/\/doi.org\/10.3390\/v14091904.","journal-title":"Viruses"},{"key":"2818_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/B978-0-12-394438-2.00004-9","volume":"83","author":"E Saussereau","year":"2012","unstructured":"Saussereau E, Debarbieux L. Bacteriophages in the experimental treatment of Pseudomonas aeruginosa infections in mice. Adv Virus Res. 2012;83:123\u201341. https:\/\/doi.org\/10.1016\/B978-0-12-394438-2.00004-9.","journal-title":"Adv Virus Res"},{"key":"2818_CR45","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/B978-0-12-374407-4.00050-9","volume":"1","author":"A Quiberoni","year":"2011","unstructured":"Quiberoni A, Su\u00e1rez V, Binetti A, Reinheimer J. Bacteriophage Enclyclopedia Dairy Sci. 2011;1:430\u20138.","journal-title":"Bacteriophage Enclyclopedia Dairy Sci"},{"key":"2818_CR46","doi-asserted-by":"publisher","unstructured":"Hyman P, Abedon ST. Bacteriophage host range and bacterial resistance. Adv Appl Microbiol Academic; 2010. pp. 217\u201348. https:\/\/doi.org\/10.1016\/S0065-2164(10)70007-1.","DOI":"10.1016\/S0065-2164(10)70007-1"},{"key":"2818_CR47","doi-asserted-by":"publisher","first-page":"100050","DOI":"10.1016\/j.crmicr.2021.100050","volume":"2","author":"S Makky","year":"2021","unstructured":"Makky S, Dawoud A, Safwat A, Abdelsattar AS, Rezk N, El-Shibiny A. The bacteriophage decides own tracks: when they are with or against the bacteria. Curr Res Microb Sci. 2021;2:100050. https:\/\/doi.org\/10.1016\/j.crmicr.2021.100050.","journal-title":"Curr Res Microb Sci"},{"key":"2818_CR48","unstructured":"SEA-PHAGES | Home. https:\/\/seaphages.org\/. Accessed 19 Apr 2025."},{"key":"2818_CR49","unstructured":"Zheng J. Phage Directory. Phage Directory. https:\/\/phage.directory\/. Accessed 21 Aug 2025."},{"key":"2818_CR50","unstructured":"PhageDive |. The database for bacteriophages and archaeal viruses. https:\/\/phagedive.dsmz.de\/. Accessed 21 Aug 2025."},{"key":"2818_CR51","unstructured":"The Actinobacteriophage Database at PhagesDB.org. The Actinobacteriophage Database at PhagesDB.org. 2010. https:\/\/phagesdb.org\/. Accessed 19 Apr 2025."},{"key":"2818_CR52","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/bioinformatics\/btw711","volume":"33","author":"DA Russell","year":"2017","unstructured":"Russell DA, Hatfull GF. PhagesDB: the actinobacteriophage database. Bioinformatics. 2017;33:784\u20136. https:\/\/doi.org\/10.1093\/bioinformatics\/btw711.","journal-title":"Bioinformatics"},{"key":"2818_CR53","doi-asserted-by":"publisher","unstructured":"Sparks IL, Derbyshire KM, Jacobs WR, Morita YS. Mycobacterium smegmatis: The Vanguard of Mycobacterial Research. J Bacteriol 205:e00337\u201322. https:\/\/doi.org\/10.1128\/jb.00337-22","DOI":"10.1128\/jb.00337-22"},{"key":"2818_CR54","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.GPP3-0026-2018","author":"GF Hatfull","year":"2018","unstructured":"Hatfull GF, Mycobacteriophages. Microbiol Spectr. 2018. https:\/\/doi.org\/10.1128\/microbiolspec.GPP3-0026-2018. 6.","journal-title":"Microbiol Spectr"},{"key":"2818_CR55","doi-asserted-by":"publisher","first-page":"e1003953","DOI":"10.1371\/journal.ppat.1003953","volume":"10","author":"GF Hatfull","year":"2014","unstructured":"Hatfull GF, Mycobacteriophages. Windows into tuberculosis. PLOS Pathog. 2014;10:e1003953. https:\/\/doi.org\/10.1371\/journal.ppat.1003953.","journal-title":"PLOS Pathog"},{"key":"2818_CR56","doi-asserted-by":"publisher","first-page":"e02194","DOI":"10.1128\/AAC.02194-18","volume":"63","author":"A Mustazzolu","year":"2019","unstructured":"Mustazzolu A, Venturelli L, Dinarelli S, Brown K, Floto RA, Dietler G, et al. A rapid unraveling of the activity and antibiotic susceptibility of mycobacteria. Antimicrob Agents Chemother. 2019;63:e02194\u201318. https:\/\/doi.org\/10.1128\/AAC.02194-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"2818_CR57","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1055\/s-0039-1693706","volume":"40","author":"CJ Richards","year":"2019","unstructured":"Richards CJ, Olivier KN. Nontuberculous mycobacteria in cystic fibrosis. Semin Respir Crit Care Med. 2019;40:737\u201350. https:\/\/doi.org\/10.1055\/s-0039-1693706.","journal-title":"Semin Respir Crit Care Med"},{"key":"2818_CR58","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/cid\/ciac453","volume":"76","author":"RM Dedrick","year":"2022","unstructured":"Dedrick RM, Smith BE, Cristinziano M, Freeman KG, Jacobs-Sera D, Belessis Y, et al. Phage therapy of mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease. Clin Infect Dis Off Publ Infect Dis Soc Am. 2022;76:103\u201312. https:\/\/doi.org\/10.1093\/cid\/ciac453.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"2818_CR59","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/v16010020","volume":"16","author":"VK Harman-McKenna","year":"2023","unstructured":"Harman-McKenna VK, De Buck J.Effective isolation and characterization of mycobacteriophages with the ability to lyse Mycobacterium avium subsp. paratuberculosis. Viruses. 2023;16:20. https:\/\/doi.org\/10.3390\/v16010020.","journal-title":"Viruses"},{"key":"2818_CR60","doi-asserted-by":"publisher","first-page":"1173894","DOI":"10.3389\/fcimb.2023.1173894","volume":"13","author":"T Nayak","year":"2023","unstructured":"Nayak T, Kakkar A, Singh RK, Jaiswal LK, Singh AK, Temple L, et al. Isolation and characterization of a novel mycobacteriophage Kashi-VT1 infecting Mycobacterium species. Front Cell Infect Microbiol. 2023;13:1173894. https:\/\/doi.org\/10.3389\/fcimb.2023.1173894.","journal-title":"Front Cell Infect Microbiol"},{"key":"2818_CR61","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.tube.2019.01.002","volume":"115","author":"RM Dedrick","year":"2019","unstructured":"Dedrick RM, Guerrero Bustamante CA, Garlena RA, Pinches RS, Cornely K, Hatfull GF. Mycobacteriophage ZoeJ: a broad host-range close relative of mycobacteriophage TM4. Tuberc Edinb Scotl. 2019;115:14\u201323. https:\/\/doi.org\/10.1016\/j.tube.2019.01.002.","journal-title":"Tuberc Edinb Scotl"},{"key":"2818_CR62","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1099\/jmm.0.46238-0","volume":"55","author":"J Rybniker","year":"2006","unstructured":"Rybniker J, Kramme S, Small PL. Host range of 14 mycobacteriophages in Mycobacterium ulcerans and seven other mycobacteria including Mycobacterium tuberculosis\u2013application for identification and susceptibility testing. J Med Microbiol. 2006;55:37\u201342. https:\/\/doi.org\/10.1099\/jmm.0.46238-0.","journal-title":"J Med Microbiol"},{"key":"2818_CR63","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1086\/343812","volume":"186","author":"L Broxmeyer","year":"2002","unstructured":"Broxmeyer L, Sosnowska D, Miltner E, Chac\u00f3n O, Wagner D, McGarvey J, et al. Killing of Mycobacterium avium and Mycobacterium tuberculosis by a Mycobacteriophage delivered by a Nonvirulent Mycobacterium: a model for phage therapy of intracellular bacterial pathogens. J Infect Dis. 2002;186:1155\u201360. https:\/\/doi.org\/10.1086\/343812.","journal-title":"J Infect Dis"},{"key":"2818_CR64","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3390\/antibiotics14080801","volume":"14","author":"A Broncano-Lavado","year":"2025","unstructured":"Broncano-Lavado A, Aguilera-Correa JJ, Roquet-Ban\u00e8res F, Kremer L, Mediero A, Seoane-Blanco M, et al. P3MA: a promising mycobacteriophage infecting Mycobacterium abscessus. Antibiotics. 2025;14:801. https:\/\/doi.org\/10.3390\/antibiotics14080801.","journal-title":"Antibiotics"},{"key":"2818_CR65","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s42003-024-06006-x","volume":"7","author":"F Yang","year":"2024","unstructured":"Yang F, Labani-Motlagh A, Bohorquez JA, Moreira JD, Ansari D, Patel S, et al. Bacteriophage therapy for the treatment of Mycobacterium tuberculosis infections in humanized mice. Commun Biol. 2024;7:294. https:\/\/doi.org\/10.1038\/s42003-024-06006-x.","journal-title":"Commun Biol"},{"key":"2818_CR66","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12866-024-03474-3","volume":"24","author":"S Jeyasankar","year":"2024","unstructured":"Jeyasankar S, Kalapala YC, Sharma PR, Agarwal R. Antibacterial efficacy of mycobacteriophages against virulent Mycobacterium tuberculosis. BMC Microbiol. 2024;24:320. https:\/\/doi.org\/10.1186\/s12866-024-03474-3.","journal-title":"BMC Microbiol"},{"key":"2818_CR67","doi-asserted-by":"publisher","first-page":"583661","DOI":"10.3389\/fmicb.2020.583661","volume":"11","author":"YC Kalapala","year":"2020","unstructured":"Kalapala YC, Sharma PR, Agarwal R. Antimycobacterial potential of mycobacteriophage under disease-mimicking conditions. Front Microbiol. 2020;11:583661. https:\/\/doi.org\/10.3389\/fmicb.2020.583661.","journal-title":"Front Microbiol"},{"key":"2818_CR68","doi-asserted-by":"publisher","first-page":"dmm049159","DOI":"10.1242\/dmm.049159","volume":"14","author":"MD Johansen","year":"2021","unstructured":"Johansen MD, Alcaraz M, Dedrick RM, Roquet-Ban\u00e8res F, Hamela C, Hatfull GF, et al. Mycobacteriophage\u2013antibiotic therapy promotes enhanced clearance of drug-resistant Mycobacterium abscessus. Dis Model Mech. 2021;14:dmm049159. https:\/\/doi.org\/10.1242\/dmm.049159.","journal-title":"Dis Model Mech"},{"key":"2818_CR69","doi-asserted-by":"publisher","first-page":"10360","DOI":"10.1038\/s41467-024-54666-4","volume":"15","author":"M Cristinziano","year":"2024","unstructured":"Cristinziano M, Shashkina E, Chen L, Xiao J, Miller MB, Doligalski C, et al. Use of epigenetically modified bacteriophage and dual beta-lactams to treat a Mycobacterium abscessus sternal wound infection. Nat Commun. 2024;15:10360. https:\/\/doi.org\/10.1038\/s41467-024-54666-4.","journal-title":"Nat Commun"},{"key":"2818_CR70","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.7150\/ijbs.60551","volume":"17","author":"X Li","year":"2021","unstructured":"Li X, He Y, Wang Z, Wei J, Hu T, Si J, et al. A combination therapy of phages and antibiotics: two is better than one. Int J Biol Sci. 2021;17:3573\u201382. https:\/\/doi.org\/10.7150\/ijbs.60551.","journal-title":"Int J Biol Sci"},{"key":"2818_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/mdr.2006.12.1","volume":"12","author":"L Danelishvili","year":"2006","unstructured":"Danelishvili L, Young LS, Bermudez LE. In vivo efficacy of phage therapy for Mycobacterium avium infection as delivered by a nonvirulent mycobacterium. Microb Drug Resist Larchmt N. 2006;12:1\u20136. https:\/\/doi.org\/10.1089\/mdr.2006.12.1.","journal-title":"Microb Drug Resist Larchmt N"},{"key":"2818_CR72","doi-asserted-by":"publisher","first-page":"e2183","DOI":"10.1371\/journal.pntd.0002183","volume":"7","author":"G Trigo","year":"2013","unstructured":"Trigo G, Martins TG, Fraga AG, Longatto-Filho A, Castro AG, Azeredo J, et al. Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model. PLoS Negl Trop Dis. 2013;7:e2183. https:\/\/doi.org\/10.1371\/journal.pntd.0002183.","journal-title":"PLoS Negl Trop Dis"},{"key":"2818_CR73","doi-asserted-by":"publisher","first-page":"e00162","DOI":"10.1128\/aac.00162-23","volume":"67","author":"K Hurst-Hess","year":"2023","unstructured":"Hurst-Hess K, Walz A, Yang Y, McGuirk H, Gonzalez-Juarrero M, Hatfull GF, et al. Intrapulmonary treatment with mycobacteriophage LysB rapidly reduces Mycobacterium abscessus burden. Antimicrob Agents Chemother. 2023;67:e00162\u201323. https:\/\/doi.org\/10.1128\/aac.00162-23.","journal-title":"Antimicrob Agents Chemother"},{"key":"2818_CR74","doi-asserted-by":"publisher","first-page":"e2318627121","DOI":"10.1073\/pnas.2318627121","volume":"121","author":"VK Harman-McKenna","year":"2024","unstructured":"Harman-McKenna VK, Eshraghisamani R, Shafer N, De Buck J. Lining the small intestine with mycobacteriophages protects from Mycobacterium avium subsp. paratuberculosis and eliminates fecal shedding. Proc Natl Acad Sci. 2024;121:e2318627121. https:\/\/doi.org\/10.1073\/pnas.2318627121.","journal-title":"Proc Natl Acad Sci"},{"key":"2818_CR75","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","volume":"25","author":"RM Dedrick","year":"2019","unstructured":"Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019;25:730\u20133. https:\/\/doi.org\/10.1038\/s41591-019-0437-z.","journal-title":"Nat Med"},{"key":"2818_CR76","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/cid\/ciac453","volume":"76","author":"RM Dedrick","year":"2023","unstructured":"Dedrick RM, Smith BE, Cristinziano M, Freeman KG, Jacobs-Sera D, Belessis Y, et al. Phage therapy of mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease. Clin Infect Dis. 2023;76:103\u201312. https:\/\/doi.org\/10.1093\/cid\/ciac453.","journal-title":"Clin Infect Dis"},{"key":"2818_CR77","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.cell.2022.04.024","volume":"185","author":"JA Nick","year":"2022","unstructured":"Nick JA, Dedrick RM, Gray AL, Vladar EK, Smith BE, Freeman KG, et al. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell. 2022;185:1860\u2013e187412. https:\/\/doi.org\/10.1016\/j.cell.2022.04.024.","journal-title":"Cell"},{"key":"2818_CR78","doi-asserted-by":"publisher","first-page":"ofaa389","DOI":"10.1093\/ofid\/ofaa389","volume":"7","author":"S Aslam","year":"2020","unstructured":"Aslam S, Lampley E, Wooten D, Karris M, Benson C, Strathdee S, et al. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. Open Forum Infect Dis. 2020;7:ofaa389. https:\/\/doi.org\/10.1093\/ofid\/ofaa389.","journal-title":"Open Forum Infect Dis"},{"key":"2818_CR79","doi-asserted-by":"publisher","first-page":"e00087","DOI":"10.1128\/asmcr.00087-24","volume":"0","author":"M Shimamura","year":"2025","unstructured":"Shimamura M, Becken B, Tansmore J, Bonomo RA, Dousa KM. Successful treatment of macrolide-resistant Mycobacterium abscessus infection using multi-drug regimens including dual \u03b2-lactams and phage therapy: case reports in two children. ASM Case Rep. 2025;0:e00087\u201324. https:\/\/doi.org\/10.1128\/asmcr.00087-24.","journal-title":"ASM Case Rep"},{"key":"2818_CR80","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/s41591-021-01403-9","volume":"27","author":"RM Dedrick","year":"2021","unstructured":"Dedrick RM, Freeman KG, Nguyen JA, Bahadirli-Talbott A, Smith BE, Wu AE, et al. Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection. Nat Med. 2021;27:1357\u201361. https:\/\/doi.org\/10.1038\/s41591-021-01403-9.","journal-title":"Nat Med"},{"key":"2818_CR81","doi-asserted-by":"publisher","first-page":"e00973","DOI":"10.1128\/mBio.00973-21","volume":"12","author":"CA Guerrero-Bustamante","year":"2021","unstructured":"Guerrero-Bustamante CA, Dedrick RM, Garlena RA, Russell DA, Hatfull GF. Toward a phage cocktail for tuberculosis: susceptibility and tuberculocidal action of mycobacteriophages against diverse mycobacterium tuberculosis strains. mBio. 2021;12:e00973\u201321. https:\/\/doi.org\/10.1128\/mBio.00973-21.","journal-title":"mBio"},{"key":"2818_CR82","first-page":"209","volume":"4","author":"L Sula","year":"1981","unstructured":"Sula L, Sulov\u00e1 J, Stolcpartov\u00e1 M. Therapy of experimental tuberculosis in guinea pigs with mycobacterial phages DS-6A, GR-21 T, My-327. Czech Med. 1981;4:209\u201314.","journal-title":"Czech Med"},{"key":"2818_CR83","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3390\/ph16121638","volume":"16","author":"B Zalewska-Pi\u0105tek","year":"2023","unstructured":"Zalewska-Pi\u0105tek B. Phage therapy\u2014challenges, opportunities and future prospects. Pharmaceuticals. 2023;16:1638. https:\/\/doi.org\/10.3390\/ph16121638.","journal-title":"Pharmaceuticals"},{"key":"2818_CR84","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3390\/ph16101347","volume":"16","author":"KM Chung","year":"2023","unstructured":"Chung KM, Nang SC, Tang SS. The safety of bacteriophages in treatment of diseases caused by multidrug-resistant bacteria. Pharmaceuticals. 2023;16:1347. https:\/\/doi.org\/10.3390\/ph16101347.","journal-title":"Pharmaceuticals"},{"key":"2818_CR85","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00284-016-1166-x","volume":"74","author":"AA Cisek","year":"2017","unstructured":"Cisek AA, D\u0105browska I, Gregorczyk KP, Wy\u017cewski Z. Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages. Curr Microbiol. 2017;74:277\u201383. https:\/\/doi.org\/10.1007\/s00284-016-1166-x.","journal-title":"Curr Microbiol"},{"key":"2818_CR86","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/v10070351","volume":"10","author":"F Oechslin","year":"2018","unstructured":"Oechslin F. Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses. 2018;10:351. https:\/\/doi.org\/10.3390\/v10070351.","journal-title":"Viruses"},{"key":"2818_CR87","doi-asserted-by":"publisher","first-page":"e00926","DOI":"10.1128\/IAI.00926-19","volume":"88","author":"MR Mangalea","year":"2020","unstructured":"Mangalea MR, Duerkop BA. Fitness trade-offs resulting from bacteriophage resistance potentiate synergistic antibacterial strategies. Infect Immun. 2020;88:e00926\u201319. https:\/\/doi.org\/10.1128\/IAI.00926-19.","journal-title":"Infect Immun"},{"key":"2818_CR88","doi-asserted-by":"publisher","first-page":"1280265","DOI":"10.3389\/fcimb.2023.1280265","volume":"13","author":"JC Garc\u00eda-Cruz","year":"2024","unstructured":"Garc\u00eda-Cruz JC, Rebollar-Juarez X, Limones-Martinez A, Santos-Lopez CS, Toya S, Maeda T, et al. Resistance against two lytic phage variants attenuates virulence and antibiotic resistance in Pseudomonas aeruginosa. Front Cell Infect Microbiol. 2024;13:1280265. https:\/\/doi.org\/10.3389\/fcimb.2023.1280265.","journal-title":"Front Cell Infect Microbiol"},{"key":"2818_CR89","doi-asserted-by":"publisher","first-page":"e03431","DOI":"10.1128\/mBio.03431-20","volume":"12","author":"RM Dedrick","year":"2021","unstructured":"Dedrick RM, Smith BE, Garlena RA, Russell DA, Aull HG, Mahalingam V, et al. Mycobacterium abscessus strain morphotype determines phage susceptibility, the repertoire of therapeutically useful phages, and phage resistance. mBio. 2021;12:e03431\u201320. https:\/\/doi.org\/10.1128\/mBio.03431-20.","journal-title":"mBio"},{"key":"2818_CR90","doi-asserted-by":"publisher","first-page":"16251","DOI":"10.1038\/nmicrobiol.2016.251","volume":"2","author":"RM Dedrick","year":"2017","unstructured":"Dedrick RM, Jacobs-Sera D, Guerrero Bustamante CA, Garlena RA, Mavrich TN, Pope WH, et al. Prophage-mediated defense against viral attack and viral counter-defense. Nat Microbiol. 2017;2:16251. https:\/\/doi.org\/10.1038\/nmicrobiol.2016.251.","journal-title":"Nat Microbiol"},{"key":"2818_CR91","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1146\/annurev-virology-122019-070009","volume":"7","author":"GF Hatfull","year":"2020","unstructured":"Hatfull GF, Actinobacteriophages. Genomics, dynamics, and applications. Annu Rev Virol. 2020;7:37\u201361. https:\/\/doi.org\/10.1146\/annurev-virology-122019-070009.","journal-title":"Annu Rev Virol"},{"key":"2818_CR92","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2147\/BTT.S381237","volume":"16","author":"Z Hibstu","year":"2022","unstructured":"Hibstu Z, Belew H, Akelew Y, Mengist HM. Phage therapy: a different approach to fight bacterial infections. Biol Targets Ther. 2022;16:173\u201386. https:\/\/doi.org\/10.2147\/BTT.S381237.","journal-title":"Biol Targets Ther"},{"key":"2818_CR93","doi-asserted-by":"publisher","first-page":"dlae017","DOI":"10.1093\/jacamr\/dlae017","volume":"6","author":"I Bleriot","year":"2024","unstructured":"Bleriot I, Pacios O, Blasco L, Fern\u00e1ndez-Garc\u00eda L, L\u00f3pez M, Ortiz-Cartagena C, et al. Improving phage therapy by evasion of phage resistance mechanisms. JAC-Antimicrob Resist. 2024;6:dlae017. https:\/\/doi.org\/10.1093\/jacamr\/dlae017.","journal-title":"JAC-Antimicrob Resist"},{"key":"2818_CR94","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s13205-024-04101-8","volume":"14","author":"A Kapoor","year":"2024","unstructured":"Kapoor A, Mudaliar SB, Bhat VG, Chakraborty I, Prasad ASB, Mazumder N. Phage therapy: a novel approach against multidrug-resistant pathogens. 3 Biotech. 2024;14:256. https:\/\/doi.org\/10.1007\/s13205-024-04101-8.","journal-title":"3 Biotech"},{"key":"2818_CR95","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/nyas.14533","volume":"1496","author":"OI North","year":"2021","unstructured":"North OI, Brown ED. Phage-antibiotic combinations: a promising approach to constrain resistance evolution in bacteria. Ann N Y Acad Sci. 2021;1496:23\u201334. https:\/\/doi.org\/10.1111\/nyas.14533.","journal-title":"Ann N Y Acad Sci"},{"key":"2818_CR96","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/ijms22020735","volume":"22","author":"A Allu\u00e9-Guardia","year":"2021","unstructured":"Allu\u00e9-Guardia A, Saranathan R, Chan J, Torrelles JB. Mycobacteriophages as potential therapeutic agents against drug-resistant tuberculosis. Int J Mol Sci. 2021;22:735. https:\/\/doi.org\/10.3390\/ijms22020735.","journal-title":"Int J Mol Sci"},{"key":"2818_CR97","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.2147\/IDR.S218638","volume":"12","author":"T Azimi","year":"2019","unstructured":"Azimi T, Mosadegh M, Nasiri MJ, Sabour S, Karimaei S, Nasser A. Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review. Infect Drug Resist. 2019;12:2943\u201359. https:\/\/doi.org\/10.2147\/IDR.S218638.","journal-title":"Infect Drug Resist"},{"key":"2818_CR98","doi-asserted-by":"publisher","unstructured":"Nguyen S, Baker K, Padman BS, Patwa R, Dunstan RA, Weston TA, et al. Bacteriophage transcytosis provides a mechanism to cross epithelial cell layers. mBio. 2017;8. https:\/\/doi.org\/10.1128\/mbio.01874-17.","DOI":"10.1128\/mbio.01874-17"},{"key":"2818_CR99","doi-asserted-by":"publisher","unstructured":"Otero J, Garc\u00eda-Rodr\u00edguez A, Cano-Sarabia M, Maspoch D, Marcos R, Cort\u00e9s P, et al. Biodistribution of liposome-encapsulated bacteriophages and their transcytosis during oral phage therapy. Front Microbiol. 2019;10. https:\/\/doi.org\/10.3389\/fmicb.2019.00689.","DOI":"10.3389\/fmicb.2019.00689"},{"key":"2818_CR100","doi-asserted-by":"publisher","first-page":"17559","DOI":"10.1038\/s41598-018-35859-6","volume":"8","author":"C M\u00f8ller-Olsen","year":"2018","unstructured":"M\u00f8ller-Olsen C, Ho SFS, Shukla RD, Feher T, Sagona AP. Engineered K1F bacteriophages kill intracellular Escherichia coli K1 in human epithelial cells. Sci Rep. 2018;8:17559. https:\/\/doi.org\/10.1038\/s41598-018-35859-6.","journal-title":"Sci Rep"},{"key":"2818_CR101","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/jam.13207","volume":"121","author":"P B\u00e1rdy","year":"2016","unstructured":"B\u00e1rdy P, Pant\u016f\u010dek R, Bene\u0161\u00edk M, Do\u0161ka\u0159 J. Genetically modified bacteriophages in applied microbiology. J Appl Microbiol. 2016;121:618\u201333. https:\/\/doi.org\/10.1111\/jam.13207.","journal-title":"J Appl Microbiol"},{"key":"2818_CR102","doi-asserted-by":"publisher","first-page":"e01874","DOI":"10.1128\/mBio.01874-17","volume":"8","author":"S Nguyen","year":"2017","unstructured":"Nguyen S, Baker K, Padman BS, Patwa R, Dunstan RA, Weston TA, et al. Bacteriophage transcytosis provides a mechanism to cross epithelial cell layers. mBio. 2017;8:e01874\u201317. https:\/\/doi.org\/10.1128\/mBio.01874-17.","journal-title":"mBio"},{"key":"2818_CR103","doi-asserted-by":"publisher","first-page":"9301","DOI":"10.3390\/ijms25179301","volume":"25","author":"X Li","year":"2024","unstructured":"Li X, Xu J, Wang Y, Gomaa SE, Zhao H, Teng T. The biological characteristics of Mycobacterium phage Henu3 and the fitness cost associated with its resistant strains. Int J Mol Sci. 2024;25:9301. https:\/\/doi.org\/10.3390\/ijms25179301.","journal-title":"Int J Mol Sci"},{"key":"2818_CR104","doi-asserted-by":"publisher","first-page":"e27932","DOI":"10.1016\/j.heliyon.2024.e27932","volume":"10","author":"LM O\u2019Connell","year":"2024","unstructured":"O\u2019Connell LM, Coffey A, O\u2019Mahony JM. Genomic analysis of seven mycobacteriophages identifies three novel species with differing phenotypic stabilities. Heliyon. 2024;10:e27932. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27932.","journal-title":"Heliyon"},{"key":"2818_CR105","doi-asserted-by":"publisher","first-page":"15242","DOI":"10.1038\/s41598-019-51742-4","volume":"9","author":"P Manohar","year":"2019","unstructured":"Manohar P, Ramesh N. Improved lyophilization conditions for long-term storage of bacteriophages. Sci Rep. 2019;9:15242. https:\/\/doi.org\/10.1038\/s41598-019-51742-4.","journal-title":"Sci Rep"},{"key":"2818_CR106","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3389\/fmicb.2019.00488","volume":"10","author":"A Ly","year":"2019","unstructured":"Ly A, Carrigy NB, Wang H, Harrison M, Sauvageau D, Martin AR, et al. Atmospheric spray freeze drying of sugar solution with phage D29. Front Microbiol. 2019;10:488. https:\/\/doi.org\/10.3389\/fmicb.2019.00488.","journal-title":"Front Microbiol"},{"key":"2818_CR107","doi-asserted-by":"publisher","first-page":"e01979","DOI":"10.1128\/AEM.01979-20","volume":"87","author":"B Loh","year":"2021","unstructured":"Loh B, Gondil VS, Manohar P, Khan FM, Yang H, Leptihn S. Encapsulation and delivery of therapeutic phages. Appl Environ Microbiol. 2021;87:e01979\u201320. https:\/\/doi.org\/10.1128\/AEM.01979-20.","journal-title":"Appl Environ Microbiol"},{"key":"2818_CR108","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3389\/fmicb.2020.01161","volume":"11","author":"L Bretaudeau","year":"2020","unstructured":"Bretaudeau L, Tremblais K, Aubrit F, Meichenin M, Arnaud I. Good Manufacturing Practice (GMP) compliance for phage therapy medicinal products. Front Microbiol. 2020;11:1161. https:\/\/doi.org\/10.3389\/fmicb.2020.01161.","journal-title":"Front Microbiol"},{"key":"2818_CR109","doi-asserted-by":"publisher","unstructured":"Suleman M, Clark JR, Bull S, Jones JD. Ethical argument for establishing good manufacturing practice for phage therapy in the UK. J Med Ethics. 2025;51. https:\/\/doi.org\/10.1136\/jme-2023-109423.","DOI":"10.1136\/jme-2023-109423"},{"key":"2818_CR110","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/s41564-025-01992-y","volume":"10","author":"S Green","year":"2025","unstructured":"Green S. Communicating the promise of phage therapy. Nat Microbiol. 2025;10:1030\u20131. https:\/\/doi.org\/10.1038\/s41564-025-01992-y.","journal-title":"Nat Microbiol"},{"key":"2818_CR111","doi-asserted-by":"publisher","first-page":"e0285824","DOI":"10.1371\/journal.pone.0285824","volume":"18","author":"S McCammon","year":"2023","unstructured":"McCammon S, Makarovs K, Banducci S, Gold V. Phage therapy and the public: increasing awareness essential to widespread use. PLoS ONE. 2023;18:e0285824. https:\/\/doi.org\/10.1371\/journal.pone.0285824.","journal-title":"PLoS ONE"},{"key":"2818_CR112","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/cid\/ciad335","volume":"77","author":"SI Green","year":"2023","unstructured":"Green SI, Clark JR, Santos HH, Weesner KE, Salazar KC, Aslam S, et al. A retrospective, observational study of 12 cases of expanded-access customized phage therapy: production, characteristics, and clinical outcomes. Clin Infect Dis. 2023;77:1079\u201391. https:\/\/doi.org\/10.1093\/cid\/ciad335.","journal-title":"Clin Infect Dis"},{"key":"2818_CR113","doi-asserted-by":"publisher","unstructured":"Lin J, Dai G, Zhang L, Xu P, Zhao P, Zhou Y et al. Case Report: Bacteriophage-antibiotic therapy for extensively drug-resistant Acinetobacter baumannii in critically ill patient with respiratory infection. Front Med. 12:1716306. https:\/\/doi.org\/10.3389\/fmed.2025.1716306","DOI":"10.3389\/fmed.2025.1716306"},{"key":"2818_CR114","doi-asserted-by":"publisher","unstructured":"Van Nieuwenhuyse B, Balcaen M, Chatzis O, Haenecour A, Derycke E, Detaille T, et al. Case report: Personalized triple phage-antibiotic combination therapy to rescue necrotizing fasciitis caused by Panton-Valentine leukocidin-producing MRSA in a 12-year-old boy. Front Cell Infect Microbiol. 2024;14. https:\/\/doi.org\/10.3389\/fcimb.2024.1354681.","DOI":"10.3389\/fcimb.2024.1354681"},{"key":"2818_CR115","doi-asserted-by":"publisher","first-page":"vbaf004","DOI":"10.1093\/bioadv\/vbaf004","volume":"5","author":"B Papudeshi","year":"2025","unstructured":"Papudeshi B, Roach MJ, Mallawaarachchi V, Bouras G, Grigson SR, Giles SK, et al. Sphae: an automated toolkit for predicting phage therapy candidates from sequencing data. Bioinforma Adv. 2025;5:vbaf004. https:\/\/doi.org\/10.1093\/bioadv\/vbaf004.","journal-title":"Bioinforma Adv"},{"key":"2818_CR116","doi-asserted-by":"publisher","first-page":"vbad101","DOI":"10.1093\/bioadv\/vbad101","volume":"3","author":"J Shang","year":"2023","unstructured":"Shang J, Peng C, Liao H, Tang X, Sun Y. PhaBOX: a web server for identifying and characterizing phage contigs in metagenomic data. Bioinforma Adv. 2023;3:vbad101. https:\/\/doi.org\/10.1093\/bioadv\/vbad101.","journal-title":"Bioinforma Adv"},{"key":"2818_CR117","doi-asserted-by":"publisher","unstructured":"Aggarwal S, Dhall A, Patiyal S, Choudhury S, Arora A, Raghava GPS. An ensemble method for prediction of phage-based therapy against bacterial infections. Front Microbiol. 2023;14. https:\/\/doi.org\/10.3389\/fmicb.2023.1148579.","DOI":"10.3389\/fmicb.2023.1148579"},{"key":"2818_CR118","unstructured":"The PhageCompass. https:\/\/phagecompass.ku.dk\/. Accessed 24 Apr 2026."},{"key":"2818_CR119","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s41030-022-00210-y","volume":"9","author":"GF Hatfull","year":"2022","unstructured":"Hatfull GF. Phage therapy for nontuberculous mycobacteria: challenges and opportunities. Pulm Ther. 2022;9:91\u2013107. https:\/\/doi.org\/10.1007\/s41030-022-00210-y.","journal-title":"Pulm Ther"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02818-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02818-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02818-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:00:45Z","timestamp":1780300845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02818-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":119,"alternative-id":["2818"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02818-7","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Max Kevane-Campbell, Simone Lieberknecht, Silvia W\u00fcrstle and Nils Wetzstein have nothing to disclose.\u00a0Raja Idris received speaker fees from Tillotts Pharma and Gilead Sciences outside the submitted work. Thomas A. Wichelhaus reports research grants from BMBF, JPIAMR, Deutsche Krebshilfe, MSD as well as speaker fees and consulting honoraria from Landes\u00e4rztekammer Hessen, Insmed, Osartis, all outside the submitted work. Maria J.G.T. Vehreschild reports grants from MSD, Heel, Roche, Tillotts; consulting fees from GILEAD, Tillotts, Pfizer, Bioaster, GSK, Ecraid, Eumedica, Bactolife, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Akademie f\u00fcr Infektionsmedizin, Astra Zeneca, bioMerieux, Biotest, DGI, European Society of Neurogastroenterology, Falk Foundation, FomF GmbH, GILEAD, GSK, Helios Kliniken, Hessisches Landessozialgericht, Infektio Forum, Janssen Cilag GmbH, Klinikum Kasseln, Landes\u00e4rztekammer Hessen, LMU Kliniken, MSD, Pfizer, Streamed up, St. Vincent Hospital, Tillotts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}